00000nam 2200000za 4500 9.847765 CaOODSP 20221107153520 cr ||||||||||| 171124s2018 onc o f000 0 eng d 9780660240114 9780660240121 CaOODSP eng n-cn--- NR16-182/2017E-PDF National Research Council Canada. Extending in vivo half-life of therapeutic proteins (L-11944) [electronic resource]. [Ottawa] : National Research Council Canada, [2018] [1] p. Issued also in French under title: Accroître la demi-vie in vivo des protéines thérapeutiques (L-11944). Caption title. "December 2017." “Post-translational modifications of therapeutic proteins are commonly made to improve their circulating half-life, thereby enhancing their efficiency. Numerous strategies have been employed towards this end, including covalent modification, such as through PEGylation, the chemical addition of chains of polyethylene glycol (PEG) to therapeutic proteins. However, PEGylation relies on chemical conjugation of PEG chains to free amino groups or engineered cysteine residues on the protein, which can lead to heterogeneously-modified proteins whose activity can be adversely affected. To address this, the NRC has developed a site-specific, two-step in vitro modification process whereby polysialic acid (PSA) is enzymatically added to existing glycans, resulting in proteins with greater stability, solubility and circulating half-life”--Highlights. Issued also in print format. Recombinant proteins Protein engineering Accroître la demi-vie in vivo des protéines thérapeutiques (L-11944) (CaOODSP)9.847777 Extending in vivo half-life of therapeutic proteins (CaOODSP)9.847766 PDF 122 KB https://publications.gc.ca/collections/collection_2018/cnrc-nrc/NR16-182-2017-eng.pdf